Dr. Neha Mehta-Shah discusses ways patients with rare blood cancers, such as lymphoma, can better understand their specific ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to recent findings by rare cancer researcher Dr. Taran Gujral, head of Fred Hutch's ...

The NIH’s National Cancer Institute (NCI) received $7.2 billion in fiscal year 2024, which went to basic research, clinical trials, and genomics. Of the over 7,000 rare diseases currently ...